Vericel (VCEL) Q1 2026 Earnings Report

The call conveyed a strongly positive operational and financial quarter: record revenue, double-digit MACI growth, materially improved margins, robust cash generation, successful sales force expansion, regulatory and manufacturing milestones, and a meaningful BARDA award. The key near-term risks are timing and contingent nature of BARDA-related revenue, the need to sustain biopsy-to-implant conversion, modest near-term margin variability due to investments, and external macro/access uncertainties. On balance, the positives substantially outweigh the challenges.

Vericel raised full-year 2026 guidance by $10 million to $326–$336 million in total revenue (≈20% growth at the midpoint), driven by a strong Q1 beat (Q1 revenue $68.4M, +30% YoY), MACI strength and expected NexoBrid BARDA procurement; MACI guidance was nudged to $282–$288M with Q2 MACI expected at ~$62.5–$63.5M (MACI Q1 $56.4M, +22%, trailing-4Q growth 23%), Burn Care guidance was raised to ~$44–$48M (Q1 Burn Care $12M, +90%+, Q2 Burn Care ~$9–$10M), and management expects ~$5–$6M of NexoBrid BARDA procurement revenue in H2 (procurement to begin in Q3) from a BARDA award up to $197M (base $35M); profitability/cash targets were reiterated with full-year gross margin ~75% (Q2 ~72%), full-year adjusted EBITDA margin ~27% (Q2 ~18%), Q1 gross margin 72% (+300 bps), adjusted EBITDA nearly $10M (Q1 adjusted EBITDA margin 14%, up ~800 bps; adj. EBITDA +195% YoY), operating cash flow $16.4M and free cash flow $15.1M (third consecutive quarter ≥$12M) and ~$211M in cash and investments at quarter end.